MedCap

MedCap invests directly from its own balance sheet as a publicly listed company rather than managing a closed-end fund. Acquisitions are funded with corporate cash, debt, or equity issuance. The permanent-capital structure means there is no requirement to exit an investment after a set holding period, which suits the long regulatory and product-adoption timelines in life science.

The firm reports three operating segments: medical technology, specialty pharmaceuticals, and assistive devices. It seeks small and medium-sized businesses with established products, stable revenue, and a position in a defensible clinical niche. The model emphasizes operational improvement over financial engineering.

It functions as a hybrid. MedCap is the listed parent, but each subsidiary runs with its own management team and operational business plan. The parent sets strategic direction, allocates capital, and provides shared expertise, while the subsidiaries handle day-to-day commercial execution. This balances central oversight with local accountability.

The primary focus is Sweden and the broader Nordic region, with distribution networks extending into Northern Europe. While the firm could consider acquisitions beyond its home market, its disclosed portfolio companies and historical deal flow are concentrated in the Nordic life-science ecosystem.

There is no fixed horizon. As a permanent-capital vehicle listed on Nasdaq Stockholm, MedCap can hold subsidiaries indefinitely. Exits typically occur only when a strategic buyer offers a valuation that exceeds the firm's own assessment of long-term hold value, or when a subsidiary's needs outgrow MedCap's ability to fund them.